Last reviewed · How we verify
Multibacillary leprosy — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Lamprene | clofazimine | Novartis | Antimycobacterial | ATP-binding cassette sub-family G member 2 | 1986-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Novartis · 1 drug in Multibacillary leprosy
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Multibacillary leprosy:
- Multibacillary leprosy treatment updates — RSS
- Multibacillary leprosy treatment updates — Atom
- Multibacillary leprosy treatment updates — JSON
Cite this brief
Drug Landscape (2026). Multibacillary leprosy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/multibacillary-leprosy. Accessed 2026-06-10.
Related
- Multibacillary leprosy full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing